Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C. Turner, Julie A. Stone, Anna Kondic et al.|Clinical Cancer Research|2018Cited by 216
Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.Tara C. Gangadhar, Adil Daud, Omid Hamid et al.|Journal of Clinical Oncology|2015Cited by 6
3344 Relationship between pembrolizumab exposure and efficacy/safety in 1016 patients (pts) with advanced or metastatic melanomaSoonmo Peter Kang, Anna Kondic, Manash Chatterjee et al.|European Journal of Cancer|2015Cited by 3
Data from Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C. Turner, Julie A. Stone, Anna Kondic et al.|Unknown|2023Cited by 0
Supplementary from Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C. Turner, Julie A. Stone, Anna Kondic et al.|Unknown|2023Cited by 0